Loading
By the time patients need CAR-T their immune cells are often exhausted by earlier treatment. Storing healthy cells early would improve manufacturing success and cut the wait.
Manufacturing failures and poor CAR-T fitness are associated with prior lines of chemotherapy, bendamustine exposure and low lymphocyte counts. Collecting and cryopreserving autologous lymphocytes at diagnosis or first relapse for patients with a high probability of later needing CAR-T (high-risk large B-cell lymphoma, high-risk myeloma) would supply fitter starting material and remove apheresis scheduling from the critical path. The proposal is a prospective banking programme with defined eligibility, consent and storage funding, and a regulatory position on the use of banked material.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy, Multiple myeloma.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.